Hetero Healthcare, where corporate social responsibility isn't just a term; it's a cornerstone of our identity. With a deep-rooted commitment to our stakeholders, communities, and society at large, we believe in fostering meaningful connections through various avenues of engagement.
At Hetero Healthcare, we recognize our multifaceted responsibilities – from ensuring the safety and efficacy of our products and services to creating a nurturing environment for our employees and contributing positively to the communities we serve. Through strategic partnerships and initiatives, we endeavour to make a tangible difference in society, one step at a time.
Our dedication to social causes is signified through our collaboration with esteemed organizations such as the AIDS Society of India (ASI) and the Institute of Medicine and Law (IML). Together, we have spearheaded initiatives like "The National Convention on Medicine and Law (NCML) 2016," a platform aimed at addressing critical medico-social issues, particularly in the realm of HIV/AIDS.
Through insightful deliberations and collaborative efforts, we've championed the cause of public health and advocacy, culminating in the submission of a comprehensive 'White Paper' to policymakers and government bodies.
Furthermore, our commitment extends beyond the confines of healthcare. We actively support initiatives that empower individuals, particularly in the realms of education and social welfare. Through partnerships with organizations dedicated to orphan care and educational advancement, we strive to create opportunities for deserving individuals to pursue higher education based on merit, fostering a brighter future for generations to come.
At Hetero Healthcare, innovation is at the heart of everything we do. By seamlessly integrating our marketing division with cutting-edge research, process chemistry, and formulation development, we not only meet but exceed industry standards, delivering unparalleled value to our customers and stakeholders alike.
Join us on our journey of social responsibility and innovation as we continue to make a meaningful impact, one endeavour at a time. Together, we can build a brighter, healthier future for all
Positioned as frontrunners in Research and Development, our targeted research endeavours deliver distinctive solutions tailored to meet the pressing medical demands of underserved populations.
Our aspiration is to be acknowledged as a pioneering pharmaceutical enterprise dedicated to fulfilling the requirements of our customers, physicians, and pharmacists. Through innovative approaches, we aim to continuously elevate standards and exceed expectations in the healthcare industry."
As a pioneering force in drug development, we are deeply entrenched in innovation. Our commitment to research serves as the cornerstone of our operations, propelling us to explore the cutting edge of scientific discovery, forge new knowledge bases, pioneer the creation of novel medicines, and enhance existing drugs. This steadfast dedication not only fuels industry growth but also advances our mission towards achieving breakthroughs in medical treatment.
In our simulation, we aim to blanket a wide expanse, stimulating our marketing team to assert our presence and meet industry demands comprehensively. Our objective: achieving 100% coverage in every territory, ensuring widespread availability of our products. For a fresh approach, we could refer to this expansive coverage as '360-degree Immersion,' signifying our commitment to leaving no corner untouched in meeting healthcare needs.
Our sales team is crucial for our pharmaceutical company's success. Leveraging their expertise to expand into larger channels and effectively reach our customers. They're good at finding different ways to connect with people, which has helped our business grow a lot. They're smart and dedicated, and they're the ones who push our company to do better and reach more goals in the pharmaceutical world.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text
COVIFOR
(Remdesivir)
Launched first generic 'COVIFOR' (Remdesivir) in India for the treatment of COVID-19 (licensing agreement with Gilead Sciences Inc.)
FLUVIR
Basic manufacturer of Oseltamivir (sub-licensing agreement with Hoffman-La Rosche, Switzerland).
TAFFIC
Launched first generic Bictegravir combination therapy in India under the brand name 'TAFFIC'.
TAFERO-EM
Launched 'TAFERO-EM', first generic fixed-dose combination of 'Emtricitabine and Tenofovir Alafenamide' in India.
MABALL
Launched biosimilar Rituximab for the treatment of chronic leukaemia.
COVIFOR
Won "Express Pharma Excellence Award for COVID-19 drug launch" rewarding our contribution to provide COVIFOR(Remdesivir) access to more than 1 lakh patients.
ITBOR
Won "Certificate of Excellence" Gold Award for ITBOR from AWACS under new introductions of "ACUTE" category amongst the top 21-50 companies for 2019.
